The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SBGL, ACAD and HMNY

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SBGL, ACAD and HMNY

NEW YORK, Aug. 03, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.        

Sibanye Gold Limited (NYSE: SBGL)
Class Period: April 7, 2017 to June 26, 2018
Lead Plaintiff Deadline: August 27, 2018

The lawsuit alleges that Sibanye Gold Limited made materially false and/or misleading statements and/or failed to disclose that: (1) Sibanye’s safety protocols were inadequate to prevent a high rate of worker death; (2) Sibanye’s mining supervisors routinely forced Company employees to work in unsafe and unlawful conditions; the foregoing issues would foreseeably subject Sibanye to heightened regulatory oversight; and (3) as a result, Sibanye’s public statements were materially false and misleading at all relevant times.

Get additional information about the SBGL lawsuit: http://www.kleinstocklaw.com/pslra-c/sibanye-gold-limited?wire=3

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
Class Period: April 29, 2016 to July 9, 2018
Lead Plaintiff Deadline: September 17, 2018

The complaint alleges that during the class period ACADIA Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) adverse events and safety concerns related to NUPLAZID threatened the drug’s initial and continuing FDA approval; (2) ACADIA engaged in business practices likely to attract regulatory scrutiny; and (3) as a result, defendants’ statements about ACADIA’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

Get additional information about the ACAD lawsuit: http://www.kleinstocklaw.com/pslra-c/acadia-pharmaceuticals-inc?wire=3

Helios and Matheson Analytics Inc. (NASDAQCM: HMNY)
Class Period: August 15, 2017 to July 26, 2018
Lead Plaintiff Deadline: October 1, 2018

The complaint alleges Helios and Matheson Analytics Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Helios was touting MoviePass’ valuation and path to profitability; (ii) MoviePass’ business model was not sustainable, (iii) consequently, Helios would run out of cash, (iv) Defendants’ actions were only reducing shareholder value, and (v) as a result of the foregoing, Defendants’ statements about Helios’ business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Get additional information about the HMNY lawsuit: http://www.kleinstocklaw.com/pslra-c/helios-and-matheson-analytics-inc?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com